QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:KNSA

Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

$14.10
-0.07 (-0.49%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.97
$14.36
50-Day Range
$13.77
$17.05
52-Week Range
$7.36
$17.19
Volume
619,410 shs
Average Volume
355,648 shs
Market Capitalization
$980.37 million
P/E Ratio
7.05
Dividend Yield
N/A
Price Target
N/A

Kiniksa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
4.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$354,638 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.29) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.31 out of 5 stars

Medical Sector

982nd out of 1,029 stocks

Pharmaceutical Preparations Industry

475th out of 501 stocks

KNSA stock logo

About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

KNSA Kiniksa Pharmaceuticals, Ltd.
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Recap: Kiniksa Pharmaceuticals Q3 Earnings
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Company Calendar

Last Earnings
11/01/2021
Today
2/03/2023
Next Earnings (Estimated)
2/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
215
Year Founded
N/A

Profitability

Net Income
$-157,920,000.00
Pretax Margin
-18.00%

Debt

Sales & Book Value

Annual Sales
$38.54 million
Book Value
$2.65 per share

Miscellaneous

Free Float
31,588,000
Market Cap
$980.37 million
Optionable
Not Optionable
Beta
-0.10

Key Executives

  • Sanj K. Patel
    Chairman & Chief Executive Officer
  • Eben P. Tessari
    Chief Operating Officer & Senior Vice President
  • Mark Ragosa
    Chief Financial Officer & Senior Vice President
  • John F. Paolini
    Chief Medical Officer & Senior Vice President
  • Chad Morin
    Chief Compliance Officer & Vice President













KNSA Stock - Frequently Asked Questions

How have KNSA shares performed in 2023?

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of the year. Since then, KNSA shares have decreased by 5.7% and is now trading at $14.12.
View the best growth stocks for 2023 here
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its earnings results on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to analyst estimates of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 80.53% and a negative trailing twelve-month return on equity of 15.66%.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (1.00%), Allspring Global Investments Holdings LLC (0.31%), Hennion & Walsh Asset Management Inc. (0.11%), Strs Ohio (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry D Quart, John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $14.12.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $981.76 million and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or $2.00 on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

The company employs 215 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.

This page (NASDAQ:KNSA) was last updated on 2/3/2023 by MarketBeat.com Staff